Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes

2012 ◽  
Vol 14 (5) ◽  
pp. 447-453 ◽  
Author(s):  
E. M. Bladbjerg ◽  
J. E. Henriksen ◽  
S. Akram ◽  
J. Gram
2018 ◽  
Vol 6 (1) ◽  
pp. e000588 ◽  
Author(s):  
Takehiro Kanamori ◽  
Yumie Takeshita ◽  
Yuki Isobe ◽  
Ken-ichiro Kato ◽  
Hirofumi Misu ◽  
...  

ObjectiveGlucose variability induces endothelial dysfunction and cardiac autonomic nerve abnormality. Here we compared the effects of mealtime insulin aspart and bedtime insulin detemir on glucose variability, endothelial function, and cardiac autonomic nerve activity among Japanese patients with type 2 diabetes.Research design and methodsForty hospitalized patients received either mealtime insulin aspart or bedtime insulin detemir treatment for 2 weeks. We assessed glucose variability indices, including M-value, SD of blood glucose level, and mean blood glucose (MBG) level. Flow-mediated dilation (FMD) of the brachial artery was measured as an index of endothelial function. Low-frequency power, high-frequency power, and the low-frequency to high-frequency power ratio (LF:HF ratio) derived via heart rate variability analysis using a Holter ECG were employed as indices of cardiac autonomic nerve function.ResultsM-values and MBG levels showed a considerably greater decrease in the insulin aspart group than in the insulin detemir group (p=0.006  vs p=0.001); no change in FMD was observed in either group. Daytime LF:HF ratio significantly decreased in the insulin aspart group but not in the insulin detemir group. Total insulin dose at endpoint in the insulin aspart group was significantly higher than that in the insulin detemir group (p<0.001).ConclusionsMealtime insulin aspart reduced glucose variability to a greater extent than bedtime insulin detemir in patients with type 2 diabetes. Despite the need for higher insulin doses, insulin aspart decreased daytime cardiac sympathetic nerve activity. These properties may subsequently help reduce cardiovascular risks.Trial registration numberUMIN000008369.


Sign in / Sign up

Export Citation Format

Share Document